Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal

Sarepta spent much of last year marching forward with its candidate SRP-9001, a gene therapy treatment for the rare but fatal Duchenne muscular dystrophy, eventually filing a BLA for an accelerated approval, with a May 29 PDUFA date and a likely adcomm on the way too.